BIVI - Micro-cap BioVie rises after getting back patent protection for its ascites treatment

BioVie (NASDAQ:BIVI) on Thursday said it had won a patent for its ascites medicine BIV201 which was expected to cover treatment with it in the U.S. until 2036. BIVI stock gained 7.1% to $1.80 in premarket trading. The U.S. Patent & Trademark Office (USPTO) issued BIVI a patent covering the use of terlipressin monotherapy to treat ascites patients who have not progressed to hepatorenal syndrome. Ascites is the painful swelling of the abdomen due to the accumulation of fluid caused by advanced liver cirrhosis. BIVI's BIV201 is a continuous infusion of terlipressin, which is a common medication not available in the U.S. or Japan to treat complications related to liver cirrhosis. The USPTO's action restored U.S. patent protection for BIV201, which had previously been lost due to a challenge to a related patent by another company. BIV201 has an orphan drug designation, and the company has an ongoing phase 2b trial evaluating the efficacy of BIV201 with standard-of-care

For further details see:

Micro-cap BioVie rises after getting back patent protection for its ascites treatment